NCT01134224View on ClinicalTrials.gov

A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

insulin degludec/insulin aspart

0.4 U/kg body weight injected subcutaneously (under the skin) once

DRUG

insulin degludec/insulin aspart

0.6 U/kg body weight injected subcutaneously (under the skin) once

DRUG

insulin degludec/insulin aspart

0.8 U/kg body weight injected subcutaneously (under the skin) once

DRUG

biphasic insulin aspart 30

0.4 U/kg body weight injected subcutaneously (under the skin) once

DRUG

biphasic insulin aspart 30

0.6 U/kg body weight injected subcutaneously (under the skin) once

DRUG

biphasic insulin aspart 30

0.8 U/kg body weight injected subcutaneously (under the skin) once

Trial Locations (1)

41460

Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY